FDA OKs expanded use of ViiV HIV med Tivicay

The FDA approves ViiV Healthcare’s Tivicay (dolutegravir) for the treatment of HIV-1 infection in children as young as four weeks old and weighing at least 3 kg, in combination with other antiretroviral treatments.

The agency approved the HIV-1 integrase strand transfer inhibitor in August 2013 for HIV-1-positive patients at least 12 years old and weighing at least 40 kg.

ViiV Healthcare is the HIV-focused joint venture between GlaxoSmithKline (GSK -0.3%), Pfizer (PFE +0.3%) and Shionogi (OTCPK:SGIOY +1.3%).

https://seekingalpha.com/news/3582747-fda-oks-expanded-use-of-viiv-hiv-med-tivicay